Roche and Zealand Pharma Strike $5.3 Billion Weight Loss Deal

The Swiss pharmaceutical giant Roche has announced a partnership with Danish biotechnology firm Zealand Pharma in a deal valued at up to $5.3 billion. The collaboration aims to develop and commercialise a promising treatment in the next-generation obesity drugs market, widening Roche’s portfolio in this rapidly growing sector.

The agreement focuses on Petrelintide, a drug developed by Zealand, which mimics the pancreatic hormone amylin and induces a faster sense of fullness. Clinical trials have demonstrated an average weight loss of 8.6 per cent over 16 weeks compared to just 1.7 per cent in the placebo group. Roche and Zealand intend to market Petrelintide as both a standalone treatment and in combination with other therapies, including a developmental weight-loss drug previously acquired by Roche for $3.1 billion from California-based Carmot Therapeutics.

Roche joins a competitive field as pharmaceutical leaders such as Novo Nordisk and Eli Lilly dominate the current market with semaglutide-based treatments, branded as Wegovy and Ozempic, and tirzepatide-based drugs like Mounjaro. Analysts predict the global obesity drug market could exceed $100 billion by the start of the next decade, encouraging fierce competition and innovation among leading biotech firms.

Under the terms of this agreement, Zealand Pharma will receive $1.65 billion in upfront payments, along with potential milestone payments that could bring the total value of the deal to $5.3 billion. Profits and losses for Petrelintide and its combination drugs will be shared between the companies in the United States and Europe, while Zealand will earn royalties from sales in other markets. Zealand has agreed to pay Roche $350 million for its contribution of a complementary drug, an amount to be deducted from milestone payments.

The collaboration places manufacturing and supply responsibilities on Roche, with production preparations already underway. Zealand’s Chief Executive, Adam Steensberg, expressed confidence in the potential of Petrelintide as a foundational therapy for weight management, addressing the unmet medical needs of people living with obesity or overweight conditions. Industry experts at Jefferies forecast peak global sales of $10 billion for Petrelintide by 2038, and analysts at Bank of America anticipate its designation as a potential best-in-class treatment.

Shares in Zealand Pharma surged by 38 per cent in Copenhagen following the announcement, while Roche recorded a 3.6 per cent increase. Conversely, Novo Nordisk shares dropped 4.3 per cent, reflecting the high stakes involved in this burgeoning market. As the biotech sector races to innovate, the Roche-Zealand partnership signals a major step forward in advancing the treatment of obesity worldwide.